Stille AB (STIL) Fair Value & Analysis
Healthcare · SE · Market cap 2.2B SEK
Fair value as of: Jul 19, 2026
From 24 valuation models · updated 21 days ago
Share price −11.3% over the past month.
Below-average quality, and screening another 43% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (kr 170.47). The favourable scenario is already priced in.
- Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (kr 70.80 to kr 170.47) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range kr 94.20 – kr 276.00 · fair‑value band kr 70.80 – kr 170.47 · the kr 240.00 price screens above the kr 136.38 fair value. Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Stille AB (STIL) currently trades at kr 240.00, while our model-based Fair Value estimate is kr 136.38, implying the stock looks roughly 43.2% overvalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Stille AB generated revenue of 617M SEK at a net margin of 10.0%. Revenue grew 38.5% year over year. It earns a return on equity of 8.8%. Net debt stands at 4.6M SEK. Fundamentals as of Jul 19, 2026
Our scenario range runs from kr 70.80 (bear case) to kr 170.47 (bull case); at kr 240.00, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 68% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -43%, STIL screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (kr 160.10) versus Growth DCF (kr 52.48). Highest evidence: Growth DCF (80).
Notify me when STIL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 63
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Stille AB develops, manufactures, and distributes medtech products in Sweden, Germany, the United Kingdom, Switzerland, North America, the United States, and internationally. It operates through the Surgical Instruments and Surgical Tables segments.
Full company description
Stille AB develops, manufactures, and distributes medtech products in Sweden, Germany, the United Kingdom, Switzerland, North America, the United States, and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut, eye, blepharoplasty, operating, vascular, tenotomy, and face-lift scissors; colon, gall duct, multi-purpose, tangential occlusion, peripheral vascular, and anastomosis clamps; skin and nerve hooks, retractors, rib spreaders, self-retaining and trachea retractors, and nasal specula; and dressing, diathermy, knot-holding, tissue, iris, dura, and vascular forceps under the STILLE, Fehling, S&T, and Surgical Holdings brands. Its Surgical Tables segment provides C-arm tables, which are surgical tables used in advanced imaging, cardiac electrophysiology, cardiovascular and vascular, gastrointestinal and abdominal, interventional radiology, neuro/spine, pain management, and pulmonary under the imagiQ and MedStone brands. The company also offers instrument care education, repair and maintenance, and inspection services. Stille AB was founded in 1841 and is headquartered in Torshälla, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Stille AB reported revenue of kr 568M in FY2025 versus kr 187M in FY2021, a compound +32.0%/yr. Reported net income was kr 55.7M in FY2025, compounding +36.4%/yr from FY2021.
of which total revenue +20.8 pp · buybacks/dilution −6.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
STIL screens 43% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Stille AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Stille AB (STIL) overvalued or undervalued?
What is the fair value of STIL?
What is the quality score of STIL?
What is the revenue of Stille AB (STIL)?
What is the net profit margin of STIL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Stille AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.